spacer
home > ict > current issue
PUBLICATIONS

International Clinical Trials

ict
Spring 2016

   
Text
PDF
Editor's Comment

Graham Hughes
introduces this issue by outlining the two sides of clinical trial data – transparency on the one hand, and protection on the other hand – among other topics.

 
view
download pdf
bullet
Clinical Trial Management
Site Activation

Head Start


First and foremost, each clinical trial needs to undergo site activation – which can be a lengthy and tiresome process, says Melissa Easy at DrugDev. There are, however, three models at hand using the most recent technology to help facilitate trial start-up.

 
view
download pdf
Paediatric Trials

On Your Doorstep


With paediatric trials becoming more common, Dr Graham Wylie at MRN states that home visits in particular are part of an increasingly patient-centric healthcare movement.


 
view
download pdf
bullet
MARKETPLACE
End Point

Activity Surge

Graham Hughes
reports on the increasing activity in M&A over the past few decades, and outlines reasons for merging and the implications for consumers and stakeholders.

 
view
download pdf
Marketing Applications

The Final Step


Representing the last hurdle in bringing a drug to market, marketing applications can be costly and time consuming to develop. Rho’s David Shoemaker presents different application models to facilitate this procedure.


 
view
download pdf
bullet
Regional trials
Regional Trials

Across the Globe


ICT takes a closer look at the clinical trial landscape in different markets – namely Latin America, the MENA region, Indonesia and finally, in the EU.

 
view
download pdf
Latin America

Susana Bule and Cláudia Carvalho at Eurotrials reveal that the Latin American market has been demonstrating great potential for clinical research and pharmaceutical development for some years now. The spending in healthcare has also been increasing, which shows the governments’ prioritisation of this matter.


 
view
download pdf
The Middle East and North Africa

Cellia Habita at ARIANNE explores clinical trials in the Middle East and North Africa, and explains why these areas should not be neglected in favour of more familiar countries.

 
view
download pdf
Indonesia

Rutger Oudejans at UBM EMEA highlights the importance of local expertise in Indonesian clinical trials, and describes why this region has gained significant value in pharma as a whole.

 
view
download pdf
European Union

Srikanth Venkataraman
at Frost & Sullivan explores patient recruitment for global clinical trials – with a focus on the EU – which he believes are going to be transformed by digital platforms and mobile technologies.

 
view
download pdf
bullet
data management & statistical analysis
Data Protection

Under Wraps

8MAN’s Jens Puhle
believes that keeping data safe from rival organisations and potential theft is paramount in pharma – with threats being closer to home than one might think.

 
view
download pdf
Clinical Trial Data

Access Denied

Graham Donaldson
at TRAC Services looks at the transparency of data versus the protection of commercially confident information in light of the latest regulations introduced to Europe.

 
view
download pdf
Data Analytics

The More, The Merrier


There is no doubt that data plays an important role in pharma – and with a growing focus on the patient in the form of personalised medicine and services, this role is set to further expand, states Wipro Ltd’s Nitin Raizada.

 
view
download pdf
Data Formatting

Preparing for SEND

Roman Radelicki
at SGS believes that implementing the standardised electronic format SEND can help streamline the process of submitting electronic data in non-clinical studies, and can further save time and money.

 
view
download pdf
bullet
Drug delivery & Therapeutics
Rare Disease Treatment

Making a Difference

World Courier’s Sue Lee
discusses the growing importance of orphan drugs, which must be produced in small quantities for a limited patient population, and questions the fact that only 5% of rare diseases have treatments available.

 
view
download pdf
bullet
Supply Chain & Manufacturing
Clinical Supply Chains

On Demand


Adaptive trial design is becoming increasingly popular, observes Catalent’s Dr Paul Ingram, before investigating its implications on supply chain efficiency.

 
view
download pdf
Logistics and Handling

Touch Point

Essangui Mbaitjongue
at Thermo King is convinced that with the help of tighter temperature guidelines, the shipment of pharmaceuticals can be facilitated – thus enabling them to reach their destination unharmed.

 
view
download pdf
bullet
Central Labs
Microbiological Labs

Driven by Results: Part 2


Olga Sazonova, Veronika Khokhlova, Maxim Belotserkovsky
and Andrey Karelin at PSI CRO continue examining quantitative urine culture studies, and consider country-specific differences.

 
view
download pdf

Cancer Therapeutics
Pharmacogenomics and Oncology

Special Treatment

United BioSource Corporation’s Dr Don Gabriel
outlines the implications of the use of pharmacogenomics – the study of individuals’ genetic variations – on oncology, and how that impacts the way patients respond to medication.


 
view
download pdf
Oncology Research

Relationships Matter

Dr Martin Lachs
at ICON examines the connection between sites and CROs when enrolling patients in oncology studies, and considers how to further improve this relationship.

 
view
download pdf
   
spacer
Edited by
Dr Graham Hughes
Consultant in
Pharmaceutical
Development

Published quarterly in
February, May,
August and November

News and Press Releases

PSI Conference 2016

2016 PSI Annual Conference at The Pullman Hotel
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

Industry Events

SMI - Cancer Vaccines

21-22 September 2016, Holiday Inn Kensington Forum, London UK

SMi Group is thrilled to present the 5th annual Cancer Vaccines conference, taking place on 21st & 22nd September 2016 in Central London, UK.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement